Status:
UNKNOWN
Anti-VEGF in Real-world
Lead Sponsor:
Wenbin Wei
Conditions:
Neovascular Age-related Macular Edema
Diabetic Macular Edema
Eligibility:
All Genders
35-80 years
Brief Summary
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases. According to FDA and China Food and Drug Administration, Ranibizumab, Aflibercept, and ...
Detailed Description
Anti-vascular endothelial growth factor therapy is the major intervention for treating ischemic retina diseases, including neovascular age-related macular edema, diabetic macula edema/non-proliferativ...
Eligibility Criteria
Inclusion
- Patients with neovascular age-related macular edema (nAMD), diabetic macula edema (DME)/non-proliferative diabetic retinopathy (NPDR)/ proliferative diabetic retinopathy (PDR), retinal vein occlusions related macular edema, and choroidal neovascular (CNV) secondary to multiple retinal diseases.
- Undergo intravitreal anti-VEGF therapy
Exclusion
- unable to receive OCT examination
- Severe corneal opacity, cataract that affect OCT examination
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2023
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT05222633
Start Date
January 1 2022
End Date
May 1 2023
Last Update
February 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wen-Bin Wei
Beijing, Beijing Municipality, China, 100730